News

Rexahn Pharmaceuticals (Rexahn) has reached an agreement to close on its previously announced licensing and stock purchase agreements with Teva Pharmaceutical (Teva) for the development of its novel

Hyperion Therapeutics (Hyperion) has reported that its investigational product HPN-100 (glycerol phenylbutyrate) has received orphan product designation from the FDA for intermittent or chronic treatment of patients with

Ranbaxy has entered into a strategic in-licensing agreement for the Indian market, with Medy-Tox, South Korea’s Botulinum -Toxin specialised Biotech Venture, for its cosmetic product, Neuronox. The introduction

China Aoxing Pharmaceutical (China Aoxing) has reported that its Clinical Trial Application (CTA) for Tilidine/Naloxone Capsules, an opioid drug with abuse resistance property, was officially approved by the

“As we reposition the Company to unlock the value of MDS businesses, we have prepared for a smooth CEO transition as part of our succession planning process,” said

Gentium has reported a total revenue of E2.61m for the second quarter ended June 30, 2009, compared to E1.86m for the second quarter of 2008. The increase is

Intarcia Therapeutics (Intarcia) has initiated enrollment for a phase 2 study comparing its proprietary drug candidate ITCA 650 (DUROS continuous delivery of exenatide) with Byetta, an FDA-approved twice-daily

Johnson & Johnson and Elan Corporation (Elan) have reported that Janseen Alzheimer Immunotherapy has completed the acquisition of substantially all of the assets and rights of Elan related

GlaxoSmithKline (GSK) and XenoPort have reported top-line results from a phase IIb clinical trial evaluating the safety and efficacy of GSK1838262/XP13512 (gabapentin enacarbil) for neuropathic pain associated with